Gene therapy and targeted toxins for glioma

Current Gene Therapy

Volumn 5, Issue 6, 2005, Pages 535-557

  King, Gwendalyn D ^a,b   Curtin, James F ^a,b   Candolfi, Marianela ^a,b   Kroeger, Kurt ^a,b   Lowenstein, Pedro R ^a,b   Castro, Maria G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4T cells; CD8T cells; Cytokines; Dendritic cells; Flt3L; Gene therapy; Glioma; HSV1 TK; Immunotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BACTERIAL TOXIN; CARBOXYPEPTIDASE G2; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; CYTOTOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUCYTOSINE; GANCICLOVIR; IMMUNOSTIMULATING AGENT; INTERFERON; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN RECEPTOR; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; ONCOLYTIC VIRUS; ONYX 015; PRODRUG; PROTEIN P53; PSEUDOMONAS EXOTOXIN; PURINE NUCLEOSIDE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; UROKINASE RECEPTOR;

ANTIGEN PRESENTING CELL; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DOSE RESPONSE; DRUG MECHANISM; EDEMA; FATIGUE; GENE TARGETING; GENE THERAPY; GENE VECTOR; GLIOBLASTOMA; GLIOMA; HEADACHE; HERPES SIMPLEX VIRUS 1; HUMAN; HYPONATREMIA; IMMUNOSTIMULATION; INTRACRANIAL HYPERTENSION; NEUROPATHY; NONHUMAN; ONCOGENE; REVIEW; SEIZURE; SPEECH DISORDER; SURVIVAL TIME; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VISUAL DISORDER;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GENE TARGETING; GENE THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY; MICE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; ONCOLYTIC VIRUSES; RECEPTORS, CELL SURFACE;

BACTERIA (MICROORGANISMS); HUMAN HERPESVIRUS 1; PSEUDOMONAS EXOTOXIN;

EID: 29444454769     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774964631     Document Type: Review

References (257)

1. Abramovitch, R., G. Meir and M. Neeman. (1995) Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res., 55(9): 1956-62.
2. Aghi, M., F. Hochberg and X. O. Breakefield. (2000) Prodrug activation enzymes in cancer gene therapy. J. Gene. Med., 2(3): 148-64.
3. Aghi, M., C. M. Kramm, T. C. Chou, X. O. Breakefield and E. A. Chiocca. (1998) Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst., 90(5): 370-80.
4. Akbasak, A., E. H. Oldfield and S. C. Saris. (1991) Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J. Neurosurg., 75(6): 922-9.
5. Albright, L., J. C. Madigan, M. R. Gaston and D. P. Houchens. (1975) Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guerin, neuraminidase-treated tumor cells, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res., 35(3): 658-65.
6. Ali, S., J. F. Curtin, J. M. Zirger, W. Xiong, G. D. King, C. Barcia, C. Liu, M. Puntel, S. Goverdhana, P. R. Lowenstein and M. G. Castro. (2004) Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand. (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther., 10(6): 1071-84.
7. Ali, S., G. D. King, J. F. Curtin, M. Candolfi, W. Xiong, C. Liu, M. Puntel, Q. Cheng, J. Prieto, A. Ribas, J. Kupiec-Wiglinski, N. van Rooijen, H. Lassmann, P. R. Lowenstein and M. G. Castro. (2005) Combined immune stimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Research, 65(16): 7194-7204.
8. Asai, A., Y. Miyagi, A. Sugiyama, M. Gamanuma, S. H. Hong, S. Takamoto, K. Nomura, M. Matsutani, K. Takakura and Y. Kuchino. (1994) Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neurooncol., 19(3): 259-68.
9. Badie, B., K. E. Drazan, M. H. Kramar, A. Shaked and K. L. Black. (1995) Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol. Res., 17(3): 209-16.
10. Badie, B., M. H. Kramar, R. Lau, D. A. Boothman, J. S. Economou and K. L. Black. (1998) Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J. Neurooncol., 37(3): 217-22.
11. Barth, R. F.. (1998) Rat brain tumor models in experimental neurooncology: the 9L, C6, T9, F98, RG2. (D74), RT-2 and CNS-1 gliomas. J. Neurooncol., 36(1): 91-102.
12. Beauchesne, P.. (2002) Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol., 20(14): 3180-1; author reply 3181.
13. Begemann, M., G. N. Fuller and E. C. Holland. (2002) Genetic modeling of glioma formation in mice. Brain Pathol., 12(1): 117-32.
14. Benedetti, S., F. Dimeco, B. Pollo, N. Cirenei, B. M. Colombo, M. G. Bruzzone, E. Cattaneo, A. Vescovi, S. Didonato, M. P. Colombo and G. Finocchiaro. (1997) Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum. Gene. Ther., 8(11): 1345-53.
15. Bi, W., Y. G. Kim, E. S. Feliciano, L. Pavelic, K. M. Wilson, Z. P. Pavelic and P. J. Stambrook. (1997) An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene. Ther., 4(4): 246-52.
16. Biglari, A., D. Bataille, U. Naumann, M. Weller, J. Zirger, M. G. Castro and P. R. Lowenstein. (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene. Ther., 11(11): 721-32.
17. Bischoff, J. R., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey and F. McCormick. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274(5286): 373-6.
18. Boviatsis, E. J., J. S. Park, M. Sena-Esteves, C. M. Kramm, M. Chase, J. T. Efird, M. X. Wei, X. O. Breakefield and E. A. Chiocca. (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 54(22): 5745-51.
19. Boviatsis, E. J., J. M. Scharf, M. Chase, K. Harrington, N. W. Kowall, X. O. Breakefield and E. A. Chiocca. (1994) Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene. Ther., 1(5): 323-31.
20. Burton, E. and M. Prados. (1999) New chemotherapy options for the treatment of malignant gliomas. Curr. Opin. Oncol., 11(3): 157-61.
21. Burton, E. C. and M. D. Prados. (2000) Malignant gliomas. Curr. Treat Options Oncol., 1(5): 459-68.
22. Caruso, M., Y. Panis, S. Gagandeep, D. Houssin, J. L. Salzmann and D. Klatzmann. (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90(15): 7024-8.
23. Castro, M. G., R. Cowen, I. K. Williamson, A. David, M. J. Jimenez-Dalmaroni, X. Yuan, A. Bigliari, J. C. Williams, J. Hu and P. R. Lowenstein. (2003) Current and future strategies for the treatment of malignant brain tumors. Pharmacol. Ther., 98(1): 71-108.
24. Chang, J. W., H. Lee, E. Kim, Y. Lee, S. S. Chung and J. H. Kim. (2000) Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. Neurosurgery, 47(4): 931-8; discussion 938-9.
25. Chang, T. K., G. F. Weber, C. L. Crespi and D. J. Waxman. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 53(23): 5629-37.
26. Chen, C. Y., Y. N. Chang, P. Ryan, M. Linscott, G. J. McGarrity and Y. L. Chiang. (1995) Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the bystander effect. Hum. Gene. Ther., 6(11): 1467-76.
27. Chen, J., T. Willingham, M. Shuford, D. Bruce, E. Rushing, Y. Smith and P. D. Nisen. (1996) Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene, 13(7): 1395-403.
28. Chen, L. and D. J. Waxman. (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55(3): 581-9.
29. Chen, Q. R., L. Zhang, W. Gasper and A. J. Mixson. (2001) Targeting tumor angiogenesis with gene therapy. Mol. Genet Metab., 74(1-2): 120-7.
30. Chen, S. H., H. D. Shine, J. C. Goodman, R. G. Grossman and S. L. Woo. (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA, 91(8): 3054-7.
31. Chiocca, E. A., K. M. Abbed, S. Tatter, D. N. Louis, F. H. Hochberg, F. Barker, J. Kracher, S. A. Grossman, J. D. Fisher, K. Carson, M. Rosenblum, T. Mikkelsen, J. Olson, J. Markert, S. Rosenfeld, L. B. Nabors, S. Brem, S. Phuphanich, S. Freeman, R. Kaplan and J. Zwiebel. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther., 10(5): 958-66.
32. Cirielli, C., K. Inyaku, M. C. Capogrossi, X. Yuan and J. A. Williams. (1999) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. J. Neurooncol., 43(2): 99-108.
33. Cobb, L. M., T. A. Connors, L. A. Elson, A. H. Khan, B. C. Mitchley, W. C. Ross and M. E. Whisson. (1969) 2,4-dinitro-5-ethyleneiminobenzamide. (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol., 18(6): 1519-27.
34. Colombo, F., M. Zanusso, L. Casentini, A. Cavaggioni, E. Franchin, P. Calvi and G. Palu. (1997) Gene stereotactic neurosurgery for recurrent malignant gliomas. Stereotact. Funct. Neurosurg., 68(1-4 Pt 1): 245-51.
35. Connors, T. A. and M. E. Whisson. (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature, 210(38): 866-7.
36. Conrad, C., C. R. Miller, Y. Ji, C. Gomez-Manzano, S. Bharara, J. S. McMurray, F. F. Lang, F. Wong, R. Sawaya, W. K. Yung and J. Fueyo. (2005) Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther., 12(3): 284-94.
37. Cowen, R. L., J. C. Williams, S. Emery, D. Blakey, J. L. Darling, P. R. Lowenstein and M. G. Castro. (2002) Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Ther., 9(11): 897-907.
38. Cowsill, C., T. D. Southgate, G. Morrissey, R. A. Dewey, A. E. Morelli, T. C. Maleniak, Z. Forrest, D. Klatzmann, G. W. Wilkinson, P. R. Lowenstein and M. G. Castro. (2000) Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene. Ther., 7(8): 679-85.
39. Dachs, G. U., J. Tupper and G. M. Tozer. (2005) From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs, 16(4): 349-59.
40. Dai, C., J. C. Celestino, Y. Okada, D. N. Louis, G. N. Fuller and E. C. Holland. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev., 15(15): 1913-25.
41. Darnell, R. B. and L. M. DeAngelis. (1993) Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341(8836): 21-2.
42. Debinski, W. and D. M. Gibo. (2000) Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol. Med., 6(5): 440-9.
43. Debinski, W., D. M. Gibo, S. W. Hulet, J. R. Connor and G. Y. Gillespie. (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res., 5(5): 985-90.
44. Debinski, W., D. M. Gibo, N. I. Obiri, A. Kealiher and R. K. Puri. (1998) Novel anti-brain tumor cytotoxins specific for cancer cells. Nat. Biotechnol., 16(5): 449-53.
45. Debinski, W., R. Miner, P. Leland, N. I. Obiri and R. K. Puri. (1996) Receptor for interleukin. (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem., 271(37): 22428-33.
46. Debinski, W., N. I. Obiri, I. Pastan and R. K. Puri. (1995) A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem., 270(28): 16775-80.
47. Debinski, W., N. I. Obiri, S. K. Powers, I. Pastan and R. K. Puri. (1995) Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res., 1(11): 1253-8.
48. Debinski, W. and I. Pastan. (1994) An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. Bioconjug. Chem., 5(1): 40-6.
49. Debinski, W., B. Slagle, D. M. Gibo, S. K. Powers and G. Y. Gillespie. (2000) Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J. Neurooncol., 48(2): 103-11.
50. Dewey, R. A., G. Morrissey, C. M. Cowsill, D. Stone, F. Bolognani, N. J. Dodd, T. D. Southgate, D. Klatzmann, H. Lassmann, M. G. Castro and P. R. Lowenstein. (1999) Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med., 5(11): 1256-63.
51. Dilber, M. S., M. R. Abedi, B. Bjorkstrand, B. Christensson, G. Gahrton, K. G. Xanthopoulos and C. I. Smith. (1996) Suicide gene therapy for plasma cell tumors. Blood, 88(6): 2192-200.
52. Dilber, M. S., M. R. Abedi, B. Christensson, B. Bjorkstrand, G. M. Kidder, C. C. Naus, G. Gahrton and C. I. Smith. (1997) Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res., 57(8): 1523-8.
53. Ding, H., L. Roncari, P. Shannon, X. Wu, N. Lau, J. Karaskova, D. H. Gutmann, J. A. Squire, A. Nagy and A. Guha. (2001) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res., 61(9): 3826-36.
54. Domin, B. A., W. B. Mahony and T. P. Zimmerman. (1993) Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol., 46(3): 503-10.
55. Dorigo, O., S. T. Turla, S. Lebedeva and R. A. Gjerset. (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J. Neurosurg., 88(3): 535-40.
56. Edwards, S. J., B. R. Dix, C. J. Myers, D. Dobson-Le, L. Huschtscha, M. Hibma, J. Royds and A. W. Braithwaite. (2002) Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J. Virol., 76(24): 12483-90.
57. Elshami, A. A., A. Saavedra, H. Zhang, J. C. Kucharczuk, D. C. Spray, G. I. Fishman, K. M. Amin, L. R. Kaiser and S. M. Albelda. (1996) Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene. Ther., 3(1): 85-92.
58. Fischer, H. G., U. Bonifas and G. Reichmann. (2000) Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J. Immunol., 164(9): 4826-34.
59. Fischer, H. G. and G. Reichmann. (2001) Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol., 166(4): 2717-26.
60. Fischer, U., S. Steffens, S. Frank, N. G. Rainov, K. Schulze-Osthoff and C. M. Kramm. (2005) Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene, 24(7): 1231-43.
61. Floeth, F. W., N. Shand, H. Bojar, H. B. Prisack, J. Felsberg, E. Neuen-Jacob, A. Aulich, K. J. Burger, W. J. Bock and F. Weber. (2001) Local inflammation and devascularization - in vivo mechanisms of the bystander effect in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther., 8(11): 843-51.
62. Frank, S., S. Steffens, U. Fischer, A. Tlolko, N. G. Rainov and C. M. Kramm. (2002) Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther., 9(2): 178-88.
63. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. L. Moolten and G. N. Abraham. (1993) The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53(21): 5274-83.
64. Freije, W. A., F. E. Castro-Vargas, Z. Fang, S. Horvath, T. Cloughesy, L. M. Liau, P. S. Mischel and S. F. Nelson. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res., 64(18): 6503-10.
65. Fueyo, J., R. Alemany, C. Gomez-Manzano, G. N. Fuller, A. Khan, C. A. Conrad, T. J. Liu, H. Jiang, M. G. Lemoine, K. Suzuki, R. Sawaya, D. T. Curiel, W. K. Yung and F. F. Lang. (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst., 95(9): 652-60.
66. Fueyo, J., C. Gomez-Manzano, R. Alemany, P. S. Lee, T. J. McDonnell, P. Mitlianga, Y. X. Shi, V. A. Levin, W. K. Yung and A. P. Kyritsis. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19(1): 2-12.
67. Fueyo, J., C. Gomez-Manzano, W. K. Yung, T. J. Liu, R. Alemany, T. J. McDonnell, X. Shi, J. S. Rao, V. A. Levin and A. P. Kyritsis. (1998) Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med., 4(6): 685-90.
68. Gadi, V. K., S. D. Alexander, W. R. Waud, P. W. Allan, W. B. Parker and E. J. Sorscher. (2003) A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther., 304(3): 1280-4.
69. Galli, R., E. Binda, U. Orfanelli, B. Cipelletti, A. Gritti, S. De Vitis, R. Fiocco, C. Foroni, F. Dimeco and A. Vescovi. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res., 64(19): 7011-21.
70. Ge, K., L. Xu, Z. Zheng, D. Xu, L. Sun and X. Liu. (1997) Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int. J. Cancer, 71(4): 675-9.
71. Geoerger, B., J. Grill, P. Opolon, J. Morizet, G. Aubert, Y. Lecluse, V. W. van Beusechem, W. R. Gerritsen, D. H. Kirn and G. Vassal. (2003) Potentiation of radiation therapy by the oncolytic adenovirus dl1520. (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer, 89(3): 577-84.
72. Germano, I. M., J. Fable, S. H. Gultekin and A. Silvers. (2003) Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J. Neurooncol., 65(3): 279-89.
73. Gjerset, R. A., S. T. Turla, R. E. Sobol, J. J. Scalise, D. Mercola, H. Collins and P. J. Hopkins. (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog, 14(4): 275-85.
74. Gondi, C. S., S. S. Lakka, D. H. Dinh, W. C. Olivero, M. Gujrati and J. S. Rao. (2004) RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene, 23(52): 8486-96.
75. Gondi, C. S., S. S. Lakka, N. Yanamandra, W. C. Olivero, D. H. Dinh, M. Gujrati, C. H. Tung, R. Weissleder and J. S. Rao. (2004) Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res., 64(12): 4069-77.
76. Goverdhana, S., M. Puntel, W. Xiong, J. Zirger, C. Barcia, J. F. Curtin, E. B. Soffer, S. Mondakar, G. D. King, J. Hu, S. A. Sciascia, M. Candolfi, P. Lowenstein and M. G. Castro. (2005) Regulatable gene expression systems for gene therapy applications:progress and future challenges. Mol. Ther., in press.
77. Greco, O. and G. U. Dachs. (2001) Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell Physiol., 187(1): 22-36.
78. Greenfield, L., V. G. Johnson and R. J. Youle. (1987) Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science, 238(4826): 536-9.
79. Hann, B. and A. Balmain. (2003) Replication of an E1B 55-kilodalton protein-deficient adenovirus. (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J. Virol., 77(21): 11588-95.
80. Harland, J., V. Papanastassiou and S. M. Brown. (2002) HSV1716 persistence in primary human glioma cells in vitro. Gene Ther., 9(17): 1194-8.
81. Harrow, S., V. Papanastassiou, J. Harland, R. Mabbs, R. Petty, M. Fraser, D. Hadley, J. Patterson, S. M. Brown and R. Rampling. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther., 11(22): 1648-58.
82. Harsh, G. R., T. S. Deisboeck, D. N. Louis, J. Hilton, M. Colvin, J. S. Silver, N. H. Qureshi, J. Kracher, D. Finkelstein, E. A. Chiocca and F. H. Hochberg. (2000) Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg., 92(5): 804-11.
83. He, B., M. Gross and B. Roizman. (1997) The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA, 94(3): 843-8.
84. Heidenreich, R., M. Machein, A. Nicolaus, A. Hilbig, C. Wild, M. Clauss, K. H. Plate and G. Breier. (2004) Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int. J. Cancer, 111(3): 348-57.
85. Heimberger, A. B., L. E. Crotty, G. E. Archer, R. E. McLendon, A. Friedman, G. Dranoff, D. D. Bigner and J. H. Sampson. (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol., 103(1): 16-25.
86. Heise, C., A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff and D. H. Kirn. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3(6): 639-45.
87. Hong, J. S., W. R. Waud, D. N. Levasseur, T. M. Townes, H. Wen, S. A. McPherson, B. A. Moore, Z. Bebok, P. W. Allan, J. A. Secrist, 3rd, W. B. Parker and E. J. Sorscher. (2004) Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Cancer Res., 64(18): 6610-5.
88. Horton, H. M., D. Anderson, P. Hernandez, K. M. Barnhart, J. A. Norman and S. E. Parker. (1999) A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc. Natl. Acad. Sci. USA, 96(4): 1553-8.
89. Huang, Z., M. K. Raychowdhury and D. J. Waxman. (2000) Impact of liver P450 reductase suppression on cyclophosphamide, activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther., 7(7): 1034-42.
90. Huber, B. E., E. A. Austin, C. A. Richards, S. T. Davis and S. S. Good. (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA, 91(17): 8302-6.
91. Husain, S. R., B. H. Joshi and R. K. Puri. (2001) Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer, 92(2): 168-75.
92. Ichikawa, T., T. Tamiya, Y. Adachi, Y. Ono, K. Matsumoto, T. Furuta, Y. Yoshida, H. Hamada and T. Ohmoto. (2000) In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther., 7(1): 74-82.
93. Immonen, A., M, Vapalahti, K. Tyynela, H. Hurskainen, A. Sandmair, R. Vanninen, G. Langford, N. Murray and S. Yla-Herttuala. (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther., 10(5): 967-72.
94. Izquierdo, M., M. Cortes, P. de Felipe, V. Martin, J. Diez-Guerra, A. Talavera and A. Perez-Higueras. (1995) Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther., 2(1): 66-9.
95. Izquierdo, M., M. L. Cortes, V. Martin, P. de Felipe, J. M. Izquierdo, A. Perez-Higueras, J. F. Paz, A. Isla and M. G. Blazquez. (1997) Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir. Suppl., 68: 111-7.
96. Izquierdo, M., V. Martin, P. de Felipe, J. M. Izquierdo, A. Perez-Higueras, M. L. Cortes, J. F. Paz, A. Isla and M. G. Blazquez. (1996) Human malignant brain tumor response to herpes simplex thymidine kinase. (HSVtk)/ganciclovir gene therapy. Gene Ther., 3(6): 491-5.
97. Johnson, V. G., C. Wrobel, D. Wilson, J. Zovickian, L, Greenfield, E. H. Oldfield and R. Youle. (1989) Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg., 70(2): 240-8.
98. Jongmans, W., K. van den Oudenalder, D. M. Tiemessen, J. Molkenboer, R. Willemsen, P. F. Mulders and E. Oosterwijk. (2003) Targeting of adenovirus to human renal cell carcinoma cells. Urology, 62(3): 559-65.
99. Jounaidi, Y. and D. J. Waxman. (2000) Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res., 60(14): 3761-9.
100. Kambara, H., T. Tamiya, Y. Ono, S. Ohtsuka, K. Terada, Y. Adachi, T. Ichikawa, H. Hamada and T. Ohmoto. (2002) Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene. Ther., 9(10): 840-5.
101. Kawakami, K., M. Kawakami, M. Kioi, S. R. Husain and R. K. Puri. (2004) Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J. Neurosurg., 101(6): 1004-11.
102. Kemp, T. J., B. D. Elzey and T. S. Griffith. (2003) Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J. Immunol., 171(1): 212-8.
103. Kim, S. H., J. H. Kim, A. Kolozsvary, S. L. Brown and S. O. Freytag. (1997) Preferential radiosensitization of 9L glioma cells transduced with HSV-tk gene by acyclovir. J. Neurooncol., 33(3): 189-94.
104. Kirsch, M., G. Schackert and P. M. Black. (2000) Anti-angiogenic treatment strategies for malignant brain tumors. J. Neurooncol., 50(1-2): 149-63.
105. Klatzmann, D., C. A. Valery, G. Bensimon, B. Marro, O. Boyer, K. Mokhtari, B. Diquet, J. L. Salzmann and J. Philippon. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase suicide gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther., 9(17): 2595-604.
106. Kleihues, P., K. J. Zulch, S. Matsumoto and U. Radke. (1970) Morphology of malignant gliomas induced in rabbits by systemic application of N-methyl-N-nitrosourea. Z. Neurol., 198(1): 65-78.
107. Kock, H., M. P. Harris, S. C. Anderson, T. Machemer, W. Hancock, S. Sutjipto, K. N. Wills, R. J. Gregory, H. M. Shepard, M. Westphal and D. C. Maneval. (1996) Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int. J. Cancer, 67(6): 808-15.
108. Kramm, C. M., D. Korholz, N. G. Rainov, T. Niehues, U. Fischer, S. Steffens, S. Frank, U. Banning, G. Horneff, H. Schroten and S. Burdach. (2002) Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient. Neuropediatrics, 33(1): 6-9.
109. Kruse, C. A., M. C. Molleston, E. P. Parks, P. M. Schiltz, B. K. Kleinschmidt-DeMasters and W. F. Hickey. (1994) A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J. Neurooncol., 22(3): 191-200.
110. Kunwar, S.. (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir. Suppl., 88: 105-11.
111. Kurozumi, K., T. Tamiya, Y. Ono, S, Otsuka, H. Kambara, Y. Adachi, T. Ichikawa, H. Hamada and T. Ohmoto. (2004) Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J. Neurooncol., 66(1-2): 117-27.
112. Lampson, L. A.. (2001) New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J. Neurooncol., 53(3): 275-87.
113. Lang, F. F., J. M. Bruner, G. N. Fuller, K. Aldape, M. D. Prados, S. Chang, M. S. Berger, M. W. McDermott, S. M. Kunwar, L. R. Junck, W. Chandler, J. A. Zwiebel, R. S. Kaplan and W. K. Yung. (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin.. Oncol., 21(13): 2508-18.
114. Laouar, Y. and I. N. Crispe. (2000) Functional flexibility in T cells: independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity 13(3): 291-301.
115. Laske, D. W., R. J. Youle and E. H. Oldfield. (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 3(12): 1362-8.
116. Lee, S. H., M. S. Kim, H. C. Kwon, I. C. Park, M. J. Park, C. T. Lee, Y. W. Kim, C. M. Kim and S. I. Hong. (2000) Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo. Int. J. Mol. Med., 6(5): 559-63.
117. Lefranc, F., J. Brotchi and R. Kiss. (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin.. Oncol., 23(10): 2411-22.
118. Li, C., W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari and D. A. Vallera. (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng., 15(5): 419-27.
119. Li, H., M. Alonso-Vanegas, M. A. Colicos, S. S. Jung, H. Lochmuller, A. F. Sadikot, G. J. Snipes, P. Seth, G. Karpati and J. Nalbantoglu. (1999) Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin. Cancer Res., 5(3): 637-42.
120. Lichtor, T. and R. P. Glick. (2003) Cytokine immuno-gene therapy for treatment of brain tumors. J. Neurooncol., 65(3): 247-59.
121. Liu, T. F., P. D. Hall, K. A. Cohen, M. C. Willingham, J. Cai, A. Thorburn and A. E. Frankel. (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin. Cancer Res., 11(1): 329-34.
122. Liu, T. F., M. C. Willingham, S. B. Tatter, K. A. Cohen, A. C. Lowe, A. Thorburn and A. E. Frankel. (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug. Chem. 14(6): 1107-14.
123. Liu, Y., M. Ehtesham, K. Samoto, C. J. Wheeler, R. C. Thompson, L. P. Villarreal, K. L. Black and J. S. Yu. (2002) In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther., 9(1): 9-15.
124. Long, Z., L. P. Li, T. Grooms, C. Lockey, K. Nader, I. Mychkovsky, S. Mueller, I. Burimski, P. Ryan, G. Kikuchi, D. Ennist, S. Marcus, E. Otto and G. McGarrity. (1998) Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum. Gene Ther., 9(8): 1165-72.
125. Long, Z., P. Lu, T. Grooms, I. Mychkovsky, T. Westley, T. Fitzgerald, S. Sharma-Chibber, N. Shand, G. McGarrity and E. Otto. (1999) Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy. Hum. Gene Ther., 10(5): 733-40.
126. Lorence, R. M., B. B. Katubig, K. W. Reichard, H. M. Reyes, A. Phuangsab, M. D. Sassetti, R. J. Walter and M. E. Peeples. (1994) Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res., 54(23): 6017-21.
127. Louis, D. N.. (1994) The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol., 53(1): 11-21.
128. Lowenstein, P. R.. (2002) Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol., 23(1): 23-30.
129. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller and J. C. Schuh. (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3(6): 625-31.
130. Ma, H. I., S. Z. Lin, Y. H. Chiang, J. Li, S. L. Chen, Y. P. Tsao and X. Xiao. (2002) Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral. (AAV) vector. Gene Ther., 9(1): 2-11.
131. Machein, M. R., W. Risau and K. H. Plate. (1999) Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum. Gene Ther., 10(7): 1117-28.
132. Madhankumar, A. B., A. Mintz and W. Debinski. (2004) Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia, 6(1): 15-22.
133. Maher, E. A., F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D.
134. Manome, Y., P. Y. Wen, L. Chen, T. Tanaka, Y. Dong, M. Yamazoe, A. Hirshowitz, D. W. Kufe and H. A. Fine. (1996) Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther., 3(6): 513-20.
135. Marais, R., R. A. Spooner, Y. Light, J. Martin and C. J. Springer. (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res., 56(20): 4735-42.
136. Marconi, P., M. Tamura, S. Moriuchi, D. M. Krisky, A. Niranjan, W. F. Goins, J. B. Cohen and J. C. Glorioso. (2000) Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther., 1(1): 71-81.
137. Markert, J. M., M. D. Medlock, S. D. Rabkin, G. Y. Gillespie, T. Todo, W. D. Hunter, C. A. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro and R. L. Martuza. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7(10): 867-74.
138. McMenamin, P. G.. (1999) Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp. Neurol., 405(4): 553-62.
139. Merlo, A.. (2003) Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg. Rev., 26(3): 145-58.
140. Mesnil, M., C. Piccoli, G. Tiraby, K. Willecke and H. Yamasaki. (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93(5): 1831-5.
141. Mineta, T., S. D. Rabkin and R. L. Martuza. (1994) Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54(15): 3963-6.
142. Mineta, T., S. D. Rabkin, T. Yazaki, W. D. Hunter and R. L. Martuza. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1(9): 938-43.
143. Mintz, A., D. M. Gibo, A. B. Madhankumar and W. Debinski. (2003) Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J. Neurooncol., 64(1-2): 117-23.
144. Mintz, A., D. M. Gibo, B. Slagle-Webb, N. D. Christensen and W. Debinski. (2002) IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia, 4(5): 388-99.
145. Mizuno, M., J. Yoshida, P. Colosi and G. Kurtzman. (1998) Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn. J Cancer Res., 89(1): 76-80.
146. Montesano, R., J. D. Vassalli, A. Baird, R. Guillemin and L. Orci. (1986) Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA, 83(19): 7297-301.
147. Moolten, F. L.. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46(10): 5276-81.
148. Mori, T., T. Abe, Y. Wakabayashi, T. Hikawa, K. Matsuo, Y. Yamada, M. Kuwano and S. Hori. (2000) Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J. Neurooncol., 46(2): 115-23.
149. Moriuchi, S., T. Oligino, D. Krisky, P. Marconi, D. Fink, J. Cohen and J. C. Glorioso. (1998) Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res., 58(24): 5731-7.
150. Nagel, G. A., W. F. Piessens, M. M. Stilmant and F. Lejeune. (1971) Evidence for tumor-specific immunity in human malignant melanoma. Eur. J. Cancer, 7(1): 41-7.
151. Nakahara, N., I. F. Pollack, W. J. Storkus, T. Wakabayashi, J. Yoshida and H. Okada. (2003) Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther., 10(7): 549-58.
152. Nanda, D., R. Vogels, M. Havenga, C. J. Avezaat, A. Bout and P. S. Smitt. (2001) Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res., 61(24): 8743-50.
153. Natsume, A., K. Tsujimura, M. Mizuno, T. Takahashi and J. Yoshida. (2000) IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J. Neurooncol., 47(2): 117-24.
154. Nestler, U., H. Wakimoto, F. Siller-Lopez, L. K. Aguilar, A. Chakravarti, A. Muzikansky, A. Stemmer-Rachamimov, E. A. Chiocca, E. Aguilar-Cordova and F. H. Hochberg. (2004) The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J. Neurooncol., 67(1-2): 177-88.
155. Niranjan, A., S. Moriuchi, L. D. Lunsford, D. Kondziolka, J. C. Flickinger, W. Fellows, S. Rajendiran, M. Tamura, J. B. Cohen and J. C. Glorioso. (2000) Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther., 2(2): 114-20.
156. Niranjan, A., D. Wolfe, M. Tamura, M. K. Soares, D. M. Krisky, L. D. Lunsford, S. Li, W. Fellows-Mayle, N. A. DeLuca, J. B. Cohen and J. C. Glorioso. (2003) Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther., 8(4): 530-42.
157. O'Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen and J. Folkman. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88(2): 277-85.
158. O'Reilly, M. S., L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage and J. Folkman. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79(2): 315-28.
159. O'Shea, C. C., L. Johnson, B. Bagus, S. Choi, C. Nicholas, A. Shen, L. Boyle, K. Pandey, C. Soria, J. Kunich, Y. Shen, G. Habets, D. Ginzinger and F. McCormick. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell, 6(6): 611-23.
160. Okada, H., I. F. Pollack, F. Lieberman, L. D. Lunsford, D. Kondziolka, D. Schiff, J. Attanucci, H. Edington, W. Chambers, P. Kalinski, D. Kinzler, T. Whiteside, E. Elder and D. Potter. (2001) Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum. Gene Ther., 12(5): 575-95.
161. Okada, H., I. F. Pollack, M. T. Lotze, L. D. Lunsford, D. Kondziolka, F. Lieberman, D. Schiff, J. Attanucci, H. Edington, W. Chambers, P. Robbins, J. Baar, D. Kinzler, T. Whiteside and E. Elder. (2000) Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum. Gene Ther., 11(4): 637-53.
162. Packer, R. J., C. Raffel, J. G. Villablanca, J. C. Tonn, S. E. Burdach, K. Burger, D. LaFond, J. G. McComb, P. H. Cogen, G. Vezina and L. P. Kapcala. (2000) Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg., 92(2): 249-54.
163. Palu, G., A. Cavaggioni, P. Calvi, E. Franchin, M. Pizzato, R. Boschetto, C. Parolin, M. Chilosi, S. Ferrini, A. Zanusso and F. Colombo. (1999) Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther., 6(3): 330-7.
164. Papanastassiou, V., R. Rampling, M. Fraser, R. Petty, D. Hadley, J. Nicoll, J. Harland, R. Mabbs and M. Brown. (2002) The potential for efficacy of the modified. (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther., 9(6): 398-406.
165. Parker, W. B., P. W. Allan, A. E. Hassan, J. A. Secrist, 3rd, E. J. Sorscher and W. R. Waud. (2003) Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 10(1): 23-9.
166. Parker, W. B., S. A. King, P. W. Allan, L. L. Bennett, Jr., J. A. Secrist, 3rd, J. A. Montgomery, K. S. Gilbert, W. R. Waud, A. H. Wells, G. Y. Gillespie and E. J. Sorscher. (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther., 8(14): 1637-44.
167. Pastan, I., V. Chaudhary and D. J. FitzGerald. (1992) Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem., 61: 331-54.
168. Paul, W. E.. (1991) Interleukin-4: a prototypic immunoregulatory lymphokine. Blood, 77(9): 1859-70.
169. Perez-Cruet, M. J., T. W. Trask, S. H. Chen, J. C. Goodman, S. L. Woo, R. G. Grossman and H. D. Shine. (1994) Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39(4): 506-11.
170. Peroulis, I., N. Jonas and M. Saleh. (2002) Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int. J. Cancer, 97(6): 839-45.
171. Petit, T., K. K. Davidson, C. Cerna, R. A. Lawrence, D. D. Von Hoff, C. Heise, D. Kirn and E. Izbicka. (2002) Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. Anticancer Drugs, 13(1): 47-50.
172. Phillips, P. C., C. Levow, M. Catterall, O. M. Colvin, I. Pastan and H. Brem. (1994) Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein. (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res., 54(4): 1008-15.
173. Phuangsab, A., R. M. Lorence, K. W. Reichard, M. E. Peeples and R. J. Walter. (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett., 172(1): 27-36.
174. Plate, K. H. and W. Risau. (1995) Angiogenesis in malignant gliomas. Glia, 15(3): 339-47.
175. Prados, M. D., M. McDermott, S. M. Chang, C. B. Wilson, J. Fick, K. W. Culver, J. Van Gilder, G. E. Keles, A. Spence and M. Berger. (2003) Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J. Neurooncol., 65(3): 269-78.
176. Puduvalli, V. K. and R. Sawaya. (2000) Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J. Neurooncol., 50(1-2): 189-200.
177. Puri, R. K.. (1995) Structure and function of interleukin-4 and its receptor. Cancer Treat. Res., 80: 143-85.
178. Puri, R. K., D. S. Hoon, P. Leland, P. Snoy, R. W. Rand, I. Pastan and R. J. Kreitman. (1996) Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res., 56(24): 5631-7.
179. Puumalainen, A. M., M. Vapalahti, R. S. Agrawal, M. Kossila, J. Laukkanen, P. Lehtolainen, H. Viita, L. Paljarvi, R. Vanninen and S. Yla-Herttuala. (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther., 9(12): 1769-74.
180. Qureshi, N. H., K. S. Bankiewicz, D. N. Louis, F. H. Hochberg, E. A. Chiocca and G. R. t. Harsh. (2000) Multicolumn infusion of gene therapy cells into human brain tumors: technical report. Neurosurgery 46(3): 663-8; discussion 668-9.
181. Rainov, N. G., (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 11(17): 2389-401.
182. Rainov, N. G., K. U. Dobberstein, M. Sena-Esteves, U. Herrlinger, C. M. Kramm, R. M. Philpot, J. Hilton, E. A. Chiocca and X. O. Breakefield. (1998) New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther., 9(9): 1261-73.
183. Rainov, N. G., C. Fels, J. W. Droege, C. Schafer, C. M. Kramm and T. C. Chou. (2001) Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther., 8(9): 662-8.
184. Rainov, N. G., C. M. Kramm, U. Banning, D. Riemann, H. J. Holzhausen, V. Heidecke, K. J. Burger, W. Burkett and D. Korholz. (2000) Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther., 7(21): 1853-8.
185. Rainov, N. G. and H. Ren. (2003) Clinical trials with retrovirus mediated gene therapy - what have we learned? J. Neurooncol., 65(3): 227-36.
186. Ram, Z., K. W. Culver, E. M. Oshiro, J. J. Viola, H. L. DeVroom, E. Otto, Z. Long, Y. Chiang, G. J. McGarrity, L. M. Muul, D. Katz, R. M. Blaese and E. H. Oldfield. (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 3(12): 1354-61.
187. Rampling, R., G. Cruickshank, V. Papanastassiou, J. Nicoll, D. Hadley, D. Brennan, R. Petty, A. MacLean, J. Harland, E. McKie, R. Mabbs and M. Brown. (2000) Toxicity evaluation of replication-competent herpes simplex virus. (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7(10): 859-66.
188. Rand, R. W., R. J. Kreitman, N. Patronas, F. Varricchio, I. Pastan and R. K. Puri. (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res., 6(6): 2157-65.
189. Recht, L., C. O. Torres, T. W. Smith, V. Raso and T. W. Griffin. (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg., 72(6): 941-5.
190. Reilly, K. M., D. A. Loisel, R. T. Bronson, M. E. McLaughlin and T. Jacks. (2000) Nfl;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet., 26(1): 109-13.
191. Rich, J. N., C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B. K. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins and M. West. (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res., 65(10): 4051-8.
192. Riley, D. J., A. Y. Nikitin and W. H. Lee. (1996) Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nat. Med., 2(12): 1316-21.
193. Saito, R., J. R. Bringas, A. Panner, M. Tamas, R. O. Pieper, M. S. Berger and K. S. Bankiewicz. (2004) Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res., 64(19): 6858-62.
194. Saleh, M., N. K. Jonas, A. Wiegmans and S. S. Stylli. (2000) The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther., 7(20): 1715-24.
195. Saleh, M., S. A. Stacker and A. F. Wilks. (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res., 56(2): 393-401.
196. Saleh, M., A. Wiegmans, Q. Malone, S. S. Stylli and A. H. Kaye. (1999) Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J. Natl. Cancer Inst., 91(5): 438-45.
197. Sampson, J. H., G. Akabani, G. E. Archer, D. D. Bigner, M. S. Berger, A. H. Friedman, H. S. Friedman, J. E. Herndon, 2nd, S. Kunwar, S. Marcus, R. E. McLendon, A. Paolino, K. Penne, J. Provenzale, J. Quinn, D. A. Reardon, J. Rich, T. Stenzel, S. Tourt-Uhlig, C. Wikstrand, T. Wong, R. Williams, F. Yuan, M. R. Zalutsky and I. Pastan. (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor. (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38. (TP-38) for the treatment of malignant brain tumors. J. Neurooncol., 65(1): 27-35.
198. Sandmair, A. M., S. Loimas, P. Puranen, A. Immonen, M. Kossila, M. Puranen, H. Hurskainen, K. Tyynela, M. Turunen, R. Vanninen, P. Lehtolainen, L. Paljarvi, R. Johansson, M. Vapalahti and S. Yla-Herttuala. (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther., 11(16): 2197-205.
199. Santambrogio, L., S. L. Belyanskaya, F. R. Fischer, B. Cipriani, C. F. Brosnan, P. Ricciardi-Castagnoli, L. J. Stern, J. L. Strominger and R. Riese. (2001) Developmental plasticity of CNS microglia. Proc. Natl. Acad. Sci. USA., 98(11): 6295-300.
200. Sasaki, M., S. Wizigmann-Voos, W. Risau and K. H. Plate. (1999) Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int. J. Dev. Neurosci., 17(5-6): 579-91.
201. Schmidt, E. E., K. Ichimura, G. Reifenberger and V. P. Collins. (1994) CDKN2. (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54(24): 6321-4.
202. Schneider, T., R. Gerhards, E. Kirches and R. Firsching. (2001) Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J. Neurooncol., 53(1): 39-46.
203. Schuler, G., B. Schuler-Thurner and R. M. Steinman. (2003) The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol., 15(2): 138-47.
204. Sebti, S. M. and A. D. Hamilton. (2000) Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 19(56): 6566-73.
205. Serafini, B., S. Columba-Cabezas, F. Di Rosa and F. Aloisi. (2000) Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol., 157(6): 1991-2002.
206. Shah, A. C., D. Benos, G. Y. Gillespie and J. M. Markert. (2003) Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol., 65(3): 203-26.
207. Shand, N., F. Weber, L. Mariani, M. Bernstein, A. Gianella-Borradori, Z. Long, A. G. Sorensen and N. Barbier. (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther., 10(14): 2325-35.
208. Sherr, C. J.. (1996) Cancer cell cycles. Science, 274(5293): 1672-7.
209. Short, M. P., B. C. Choi, J. K. Lee, A. Malick, X. O. Breakefield and R. L. Martuza. (1990) Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res., 27(3): 427-39.
210. Simon, M., C. Simon, G. Koster, V. H. Hans and J. Schramm. (2002) Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression. J. Neurooncol., 60(1): 1-12.
211. Singh, R. P. and R. Agarwal. (2003) Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr. Cancer Drug Targets, 3(3): 205-17.
212. Singh, S. K., C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano and P. B. Dirks. (2004) Identification of human brain tumour initiating cells. Nature, 432(7015): 396-401.
213. Smitt, P. S., M. Driesse, J. Wolbers, M. Kros and C. Avezaat. (2003) Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol. Ther., 7(6): 851-8.
214. Springer, C. J., P. Antoniw, K. D. Bagshawe, F. Searle, G. M. Bisset and M. Jarman. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem., 33(2): 677-81.
215. Springer, C. J. and I. Niculescu-Duvaz. (2000) Prodrug-activating systems in suicide gene therapy. J. Clin. Invest., 105(9): 1161-7.
216. Steiner, H. H., M. M. Bonsanto, P. Beckhove, M. Brysch, K. Geletneky, R. Ahmadi, R. Schuele-Freyer, P. Kremer, G. Ranaie, D. Matejic, H. Bauer, M. Kiessling, S. Kunze, V. Schirrmacher and C. Herold-Mende. (2004) Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol., 22(21): 4272-81.
217. Stratmann, A., M. R. Machein and K. H. Plate. (1997) Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir. Suppl.. (Wien) 68: 105-10.
218. Stribbling, S. M., F. Friedlos, J. Martin, L. Davies, R. A. Spooner, R. Marais and C. J. Springer. (2000) Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Ther., 11(2): 285-92.
219. Szabo, S. and Z. Sandor. (1998) The diagnostic and prognostic value of tumor angiogenesis. Eur. J. Surg. Suppl.. (582): 99-103.
220. Takamiya, Y., M. P. Short, F. L. Moolten, C. Fleet, T. Mineta, X. O. Breakefield and R. L. Martuza. (1993) An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg., 79(1): 104-10.
221. Tanaka, T., Y. Cao, J. Folkman and H. A. Fine. (1998) Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res., 58(15): 3362-9.
222. Tanaka, T., Y. Manome, P. Wen, D. W. Kufe and H. A. Fine. (1997) Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med., 3(4): 437-42.
223. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro and P. R. Lowenstein. (2000) Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. USA, 97(13): 7482-7.
224. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro and P. R. Lowenstein. (2001) Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene. Ther., 12(7): 839-46.
225. Todhunter, D. A., W. A. Hall, E. Rustamzadeh, Y. Shu, S. O. Doumbia and D. A. Vallera. (2004) A bispecific immunotoxin. (DTAT13) targeting human IL-13 receptor. (IL-13R) and urokinase-type plasminogen activator receptor. (uPAR) in a mouse xenograft model. Protein Eng. Des. Sel., 17(2): 157-64.
226. Tosi, D., R. Valenti, A. Cova, G. Sovena, V. Huber, L. Pilla, F. Arienti, F. Belardelli, G. Parmiani and L. Rivoltini. (2004) Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J. Immunol., 172(9): 5363-70.
227. Touraine, R. L., N. Vahanian, W. J. Ramsey and R. M. Blaese. (1998) Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther., 9(16): 2385-91.
228. Trask, T. W., R. P. Trask, E. Aguilar-Cordova, H. D. Shine, P. R. Wyde, J. C. Goodman, W. J. Hamilton, A. Rojas-Martinez, S. H. Chen, S. L. Woo and R. G. Grossman. (2000) Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther., 1(2): 195-203.
229. Trinh, Q. T., E. A. Austin, D. M. Murray, V. C. Knick and B. E. Huber. (1995) Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res., 55(21): 4808-12.
230. Tsugawa, T., N. Kuwashima, H. Sato, W. K. Fellows-Mayle, J. E. Dusak, K. Okada, G. D. Papworth, S. C. Watkins, A. Gambotto, J. Yoshida, I. F. Pollack and H. Okada. (2004) Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther., 11(21): 1551-8.
231. Tunici, P., L. Bissola, E. Lualdi, B. Pollo, L. Cajola, G. Broggi, G. Sozzi and G. Finocchiaro. (2004) Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol. Cancer, 3(1): 25.
232. Tzeng, J. J., R. F. Barth, C. G. Orosz and S. M. James, (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res., 51(9): 2373-8.
233. Ueki, K., Y. Ono, J. W. Henson, J. T. Efird, A. von Deimling and D. N. Louis. (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56(1): 150-3.
234. Valerie, K., D. Brust, J. Farnsworth, C. Amir, M. M. Taher, C. Hershey and J. Feden. (2000) Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther., 7(6): 879-84.
235. Vecil, G. G. and F. F. Lang. (2003) Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol., 65(3): 237-46.
236. Vile, R. G., S. Castleden, J. Marshall, R. Camplejohn, C. Upton and H. Chong. (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer, 71(2): 267-74.
237. Vincent, A. J., R. Vogels, G. V. Someren, M. C. Esandi, J. L. Noteboom, C. J. Avezaat, C. Vecht, D. W. Bekkum, D. Valerio, A. Bout and P. M. Hoogerbrugge. (1996) Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum. Gene Ther., 7(2): 197-205.
238. Voges, J., R. Reszka, A. Gossmann, C. Dittmar, R. Richter, G. Garlip, L. Kracht, H. H. Coenen, V. Sturm, K. Wienhard, W. D. Heiss and A. H. Jacobs. (2003) Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol., 54(4): 479-87.
239. Wang, T. J., M. S. Huang, C. Y. Hong, V. Tse, G. D. Silverberg and M. Hsiao. (2001) Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ Biochem. Biophys. Res. Commun., 287(1): 173-80.
240. Wang, W. J., C. K. Tai, N. Kasahara and T. C. Chen. (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum. Gene Ther., 14(2): 117-27.
241. Weaver, M. and D. W. Laske. (2003) Transferrin receptor ligand-targeted toxin conjugate. (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol., 65(1): 3-13.
242. Weber, F., A. Asher, R. Bucholz, M. Berger, M. Prados, S. Chang, J. Bruce, W. Hall, N. G. Rainov, M. Westphal, R. E. Warnick, R. W. Rand, F. Floeth, F. Rommel, H. Pan, V. N. Hingorani and R. K. Puri. (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin. (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol., 64(1-2): 125-37.
243. Weber, F. W., F. Floeth, A. Asher, R. Bucholz, M. Berger, M. Prados, S. Chang, J. Bruce, W. Nall, N. G. Rainov, M. Westphal, R. E. Warnick, R. W. Rand, F. Rommell, H. Pan, V. N. Hingorani and R. K. Puri. (2003) Local convection enhanced delivery of IL4-Pseudomonas exotoxin. (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl., 88: 93-103.
244. Wei, M. X., T. Tamiya, M. Chase, E. J. Boviatsis, T. K. Chang, N. W. Kowall, F. H. Hochberg, D. J. Waxman, X. O. Breakefield and E. A. Chiocca. (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5(8): 969-78.
245. Wei, M. X., T. Tamiya, R. J. Rhee, X. O. Breakefield and E. A. Chiocca. (1995) Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin. Cancer Res., 1(10): 1171-7.
246. Weiner, N. E., R. B. Pyles, C. L. Chalk, M. G. Balko, M. A. Miller, C. A. Dyer, R. E. Warnick and L. M. Parysek. (1999) A syngeneic mouse glioma model for study of glioblastoma therapy. J. Neuropathol. Exp. Neurol., 58(1): 54-60.
247. Weingart, J., L. Strauss, S. Grossman, J. Markert, S. Tatter, J. D. Fisher, C. Fleming and R. K. Puri. (2002) Phase I/II study: intra-tumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neurooncology, 4: 379.
248. Weissenberger, J., J. P. Steinbach, G. Malin, S. Spada, T. Rulicke and A. Aguzzi. (1997) Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene, 14(17): 2005-13.
249. Wiewrodt, R., K. Amin, M. Kiefer, V. P. Jovanovic, V. Kapoor, S. Force, M. Chang, M. Lanuti, M. E. Black, L. R. Kaiser and S. M. Albelda. (2003) Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther., 10(5): 353-64.
250. Wilson, K. M., P. J. Stambrook, W. L. Bi, Z. P. Pavelic, L. Pavelic and J. L. Gluckman. (1996) HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. Arch Otolaryngol. Head Neck. Surg., 122(7): 746-9.
251. Witte, J. S., L. J. Palmer, R. D. O'Connor, P. J. Hopkins and J. M. Hall. (2002) Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. Eur. J. Hum. Genet., 10(1): 82-5.
252. Yamanaka, R., S. A. Zullo, J. Ramsey, M. Onodera, R. Tanaka, M. Blaese and K. G. Xanthopoulos. (2001) Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther., 8(10): 796-802.
253. Yang, I., T. J. Kremen, A. J. Giovannone, E. Paik, S. K. Odesa, R. M. Prins and L. M. Liau. (2004) Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J. Neurosurg., 100(2): 310-9.
254. Yoshida, J., M. Mizuno, N. Nakahara and P. Colosi. (2002) Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma. Jpn. J. Cancer Res., 93(2): 223-8.
255. Yoshida, J., M. Mizuno and T. Wakabayashi. (2004) Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci., 95(11): 858-65.
256. Yuan, X., J. Curtin, Y. Xiong, G. Liu, S. Waschsmann-Hogiu, D. L. Farkas, K. L. Black and J. S. Yu. (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23(58): 9392-400.
257. Yukawa, H., J. C. Takahashi, S. I. Miyatake, M. Saiki, N. Matsuoka, M. Akimoto, H. Yanamoto, I. Nagata, H. Kikuchi and N. Hashimoto. (2000) Adenoviral gene transfer of basic fibroblast growth factor promotes angiogenesis in rat brain. Gene Ther., 7(11): 942-9.